Evidence map›Paper›PMID 39188060›Full record

ArticleThe clinical respiratory journal2024

Whole-Exome Sequencing and Experimental Validation Unveil the Roles of TMEM229A Q200del Mutation in Lung Adenocarcinoma.

Yi-Xian Liang, Yan-Ping Xie, Huan-Ming Yu, Wen-Juan Zhu, Cheng-Yi Yin, Zhao-Hui Dong, Xi-Lin Zhang

Abstract read
In one paragraph

Article in The clinical respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi-Xian LiangDepartment of Cardiothoracic Surgery, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
Yan-Ping XieDepartment of Respiratory Medicine, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
Huan-Ming YuDepartment of Cardiothoracic Surgery, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
Wen-Juan ZhuDepartment of Pathology, The First People's Hospital of Huzhou, Huzhou, Zhejiang, People's Republic of China.
Cheng-Yi YinDepartment of Cardiothoracic Surgery, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
Zhao-Hui DongDepartment of Respiratory Medicine, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
Xi-Lin ZhangCentral Laboratory, Huzhou Key Laboratory of Translational Medicine, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.ORCID https://orcid.org/0009-0006-3842-9322

Funding

Huzhou Science and Technology Fund 2021GZB03The Scientific Technology Projects of Health and Medicine of Zhejiang Province 2023KY1180Zhejiang Provincial Natural Science Foundation of China LTGY23H160004Zhejiang Provincial Natural Science Foundation of China LY22H160026
6 · The paper itself

Abstract

introductionLung adenocarcinoma (LUAD) is one of the major histopathological types of non-small cell lung cancer (NSCLC), including solid, acinar, lepidic, papillary and micropapillary subtypes. Increasing evidence has shown that micropapillary LUAD is positively associated with a higher percentage of driver gene mutations, a higher incidence of metastasis and a poorer prognosis, while lepidic LUAD has a relatively better prognosis. However, the novel genetic change and its underlying mechanism in the progression of micropapillary LUAD have not been exactly determined.

methodsA total of 181 patients with LUAD who underwent surgery at the First Affiliated Hospital of Huzhou University from January 2020 to December 2022 were enrolled. Three predominant lepidic and three predominant micropapillary LUAD tissue samples were carried out using whole-exome sequencing. Comprehensive analysis of genomic variations and the difference between lepidic and micropapillary LUAD was performed. In addition, the TMEM229A Q200del mutation was verified using our cohort and TCGA-LUAD datasets. The correlations between the TMEM229A Q200del mutation and the clinicopathological characteristics of patients with LUAD were further analyzed. The functions and mechanisms of TMEM229A Q200del on NSCLC cell proliferation and migration were also determined.

resultsThe frequency of genomic changes in patients with micropapillary LUAD was higher than that in patients with lepidic LUAD. Mutations in EGFR, ATXN2, C14orf180, MUC12, NOTCH1, and PKD1L2 were concomitantly detected in three predominant micropapillary and three predominant lepidic LUAD cases. The TMEM229A Q200del mutation was only mutated in lepidic LUAD. Additionally, the TMEM229A Q200del mutation had occurred in 16 (8.8%) patients, and not found TMEM229A R76H and M346T mutations in our cohort, while TMEM229A mutations (R76H, M346T, and Q200del) occurred only in 1.0% of the TCGA-LUAD cohort. Further correlation analysis between the TMEM229A Q200del mutation and clinicopathological characteristics suggested that a lower frequency of the Q200del mutation was significantly associated with positive lymph node metastasis, advanced TNM stage, positive cancer thrombus, and pathological features. Finally, overexpression of TMEM229A Q200del suppressed NSCLC cell proliferation and migration in vitro. Mechanistically, overexpression of TMEM229A and TMEM229A Q200del both reduced the expression level of phosphorylated (p)-ERK and p-AKT (Ser473), and the reduced protein level of p-ERK in the TMEM229A Q200del group was more pronounced compared to the TMEM229A group.

conclusionOur results demonstrated that the TMEM229A Q200del mutant may play a protective role in the progression of LUAD via inactivating ERK pathway, providing a potential therapeutic target in LUAD.

Indexed as

Adenocarcinoma of LungExome SequencingLung NeoplasmsMembrane ProteinsMutationAgedCarcinoma, Non-Small-Cell LungCell MovementCell ProliferationFemaleHumansMaleMiddle AgedPrognosisMembrane Proteinslung adenocarcinomamicropapillary componentmutationtransmembrane protein 229Awhole‐exome sequencing

Identifiers

PMID39188060
PMCPMC11347615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.